Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production

详细信息    查看全文

• 作者：Michael A. Collier ; Eric M. Bachelder ; Kristy M. Ainslie
• 关键词：KEY WORDSdoxorubicin ; drug delivery ; electrospray ; liposomes ; scalable
• 刊名：Pharmaceutical Research
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：34
• 期：2
• 页码：419-426
• 全文大小：
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Pharmacology/Toxicology; Pharmacy; Biochemistry, general; Medical Law; Biomedical Engineering;
• 出版者：Springer US
• ISSN：1573-904X
• 卷排序：34

文摘

PurposeAlthough doxorubicin (DXR) has been on the market for many years as an anti-cancer drug, a number of serious dose-limiting toxicities hinder its widespread use. To reduce the known toxicities of soluble DXR, various liposomes have been designed including Doxil, Caelyx, and Myocet. Myocet, a non-PEGylated liposomal formulation containing DXR, was found to reduce the toxicities associated with soluble DXR and has been used in Europe and Canada (but not the US) as a first line therapy. While regarded as successful, Myocet does have some formulation drawbacks including stability, drug release, and an arduous formulation and remote loading method for preparation.